{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Appendix M', 'List of Opportunistic Infections', 'Aspergillosis', 'Blastomyces dermatitidis (pathogenic fungus causing blastomycosis; endemic in the', 'south-eastern and south-central states of the US and along Mississippi and Ohio Rivers)', 'Candidiasis - only systemic or extensive mucosal or cutaneous cases of yeast infection.', 'Coccidioides immitis (pathogenic fungus causing coccidiosis; endemic south-western US', 'and Central and South America)', 'Cryptococcus', 'Cytomegalovirus', 'Herpes Simplex (disseminated)', 'Herpes Zoster (disseminated, ophthalmic; or involvement of 2 or more dermatomes)', 'Histoplasmosis (pulmonary or disseminated; most common tropical areas [eg,', 'Tennessee-Ohio-Mississippi river basins])', 'Listeriosis', 'Non-tuberculous mycobacteria (NTM), including Mycobacterium avium complex (MAC)', 'Pneumocystis pneumoniae (pathogenic fungus causing pneumocystis pneumonia)', 'NOTE: This list is indicative and not exhaustive.', 'Property of the Sanofi Group - strictly confidential', 'Page 171', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Appendix N', 'Country specific requirements', 'Amendment for Brazil dated 02-Feb-2018', 'Section 8.8.1 Prohibited medication (Section 8.8.1)', 'In Brazil, due to the Yellow Fever outbreak, any patient who is not previously vaccinated with the', 'yellow-fever vaccine (in the outbreak affected area) should be unblinded and should be', 'permanently discontinued from treatment with study drug (Section 10.3.3). Patients who', 'discontinue IMP must continue to be followed in the study until EOS (Section 10.3.4).', 'Section 9.3.1.1.1 Sampling time (Section 9.3.1.1.1)', 'Predose blood samples will be collected for determination of functional dupilumab concentration', 'in serum and anti-dupilumab antibodies (including neutralizing antibodies) on days designated in', 'the Study Flow Chart (see Section 1.2 as well as Section 10.3.4, as needed for Brazil).', 'Section 10.3.3 List of criteria for permanent discontinuation (Section 10.3.3)', 'At the specific request of the Sponsor', '-', 'Including some specific circumstances like the Yellow Fever outbreak in Brazil, where', 'patients from affected areas who are not previously vaccinated with yellow-fever', 'vaccine, are to be permanently discontinued from study drug (see below).', 'Section 10.3.4 Handling of patients after permanent treatment discontinuation', '(Section 10.3.4)', 'In Brazil, any patient who is permanently discontinued from treatment with study drug due to the', 'Yellow Fever outbreak must complete all EOT procedures. These patients should continue to be', 'followed in the study until EOS. Specific blood samples for ADA, dupilumab PK, and', 'pre-vaccination Yellow Fever antibody titer should be performed, when possible, prior to', 'vaccination in patients who received dupilumab. Post-vaccine blood samples for ADA, PK, and', 'Yellow Fever antibody titers will also be collected following the appropriate interval (4-6 weeks', 'after vaccination and may be extended up to 8 weeks). A specific ICF must be signed prior to', 'collection of these samples (See below).', 'Brazilian patients who are discontinued early from treatment due to the Yellow Fever outbreak', 'will remain eligible for the 1 year long term extension study.', 'Section 12.2 Informed consent (Section 12.2)', 'For Brazil, a country-specific ICF will be issued for the collection of additional blood samples for', 'the assessment of pre and post Yellow Fever vaccination titers, dupilumab PK, and ADA levels.', \"Refusal to sign the additional ICF will not impact the patient's ability to receive Yellow Fever\", 'vaccination.', 'Property of the Sanofi Group - strictly confidential', 'Page 172', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Appendix o', 'Protocol amendment history', 'The Protocol Amendment Summary of Changes Table for the current amended protocol03 is', 'located directly before the Table of Contents (TOC).', 'Amended protocol 02 dated 18-Jun-2018:', 'Property of the Sanofi Group - strictly confidential', 'Page 173', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}